A Partner or JV doesn't Seem Likely NearTerm
PW has stated clearly that they will go it alone
with their flagship RPE product. His reasoning
is the fact that there are only 2000 retina specialists,
and other good reasons as well. market potential,
unmet need, etc
And I think the RPE is the primary focus of the company
for now. Don't forget everything has to go through the FDA.
HOWEVER, OCAT has so many things that COULD be JV'd,
the animal stuff, the platelets, the iMCs, and all of their
processes could be licenced. Ocata will have multiple
wellsprings of income streams bursting out in all
directions.
The RPE therapy will trail blaze a foot path through
the FDA jungle, then everything will quickly stream out.
The SPA is such, good, good, news.
